Sees $133M-$153M in revenue in 1H26, $203M-$226M in 2H. Sees FY26 adjusted EBITDA $80M-$100M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- HROW Upcoming Earnings Report: What to Expect?
- TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
- Harrow management to meet with Craig-Hallum
- Harrow announces PharmaPack Direct-to-Prescriber cash-pay offering
- Earlier Opuviz Launch and Expanding Ophthalmic Franchise Underpin Harrow Buy Rating and Multi‑Year Growth Outlook